This activity is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Download Slides
    Download Practice Aid
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Practice Aid
    CORRECT!
    Next Step
    Faculty & Disclosures
    Dr Marc Steben

    HPV Global Action and Université de Montréal, Montréal, Canada

    Dr Marc Steben, a general practitioner specializing in sexual health, seeks to implement emerging best practices globally in this area. read more

    He has been appointed president of the International Society for Sexually Transmitted Diseases Research and will chair its global conference in 2025 (STI & HIV 2025 World Congress). He was president of the 26th international conference on HPV in Montréal in 2010 and introduced the first public health workshop there. He is a member of the International Papillomavirus Society board and is responsible for the training committee.

    Dr Steben is co-president of HPV Global Action, and is a member of the US National Institutes of Health/National Cancer Institute consortium on Automated Visual Examination for Papilloma Virus in Eswatini. This project is part of former President Joe Biden’s Moonshot for cancer project.

    He is the recipient of the Gilles-des Rosiers prize in medical training from the Federation of General Practitioners of Quebec, the Doctor of Heart and Action prize from the Association of French-speaking Physicians of Canada, and has received recognition medals from the Coalition Priorité Cancer and the 150th anniversary of the Faculty of Medicine of the University of Montréal. He is Ambassador Emeritus of the Palais des Congrès de Montréal.

    Disclosures

    Dr Marc Steben discloses: Consultant/advisory fees from GSK and Merck. Speakers’ bureau fees from GSK and Merck. Other fees from Abbott, Attila, GSK, Hologic, Laboratoire Médical Biron, Merck and Roche Molecular Systems. Grant/research fees from Abbott, Attila, GSK, Hologic, Laboratoire Médical Biron, Linepharma, Lupin, Merck, Project PAVE and Project INTEGRATE, and Roche Molecular Systems. Ownership fees from Communications Action-Santé Inc.
    Dr Barbara Moscicki

    UCLA Health and University of California Los Angeles, Los Angeles, CA, USA

    Dr Moscicki is a paediatrician, board certified in adolescent medicine. She is the current division chief of Adolescent and Young Adult Medicine with clinical expertise in reproductive healthcare for menstrual irregularities, sexual health and sexually-transmitted diseases (STDs). read more

    Dr Moscicki has expertise in human papillomavirus (HPV)-related disease, including diagnosis of cervical dysplasia and treatment. She also offers medical care for women with eating disorders.

    Dr Moscicki received her MD at Northwestern University and completed her residency at Vanderbilt Children’s Hospital and her fellowship in adolescent medicine at University of California, San Francisco (UCSF). In addition, she completed a fellowship in STD epidemiology and a molecular virology fellowship at Stanford University as a Howard Hughes Fellow. Prior to coming to University of California, Los Angeles (UCLA) in 2015, Dr Moscicki was a faculty member at UCSF for 30 years.

    Dr Moscicki’s 35-year research career has focused on STD epidemiology. A large focus has been on describing the natural history of HPV in adolescents and young women, transmission dynamics of HPV as well as studying the local and systemic immune responses to HPV. In addition, she has worked extensively on studying HPV among young people living with HIV. Her work has been translated to public health policies guiding ages to vaccinate against HPV, screening for cervical cancer, and management of abnormal cytology and histology. More recently, her work focuses on the vaginal microbiome and its impact on HPV progression.

    Disclosures

    Dr Barbara Moscicki discloses: Advisory board or panel fees from Merck.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    Now Playing:
    Up Next:
    Take CE/CME Test
    Start activity

    Poll

    Which of the following is the biggest barrier to HPV vaccine uptake?

    Submit your answer to see the results

    Misinformation / disinformation about vaccine efficacy / safety
       
    Cost
       
    Lack of a strong vaccine recommendation from an HCP
       
    Lack of awareness about the benefits or purpose of vaccination
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    What is your view on the off-label single-dose HPV vaccination schedule?

    Submit your answer to see the results

    I do not support using a single-dose schedule
       
    Appropriate for some countries
       
    Appropriate globally
       
    More evidence is needed before deciding
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    What do you see as the biggest emerging challenge in HPV-related disease?

    Submit your answer to see the results

    Increases in penile, vaginal and vulval cancers
       
    Increases in anal cancer
       
    Increases in oropharyngeal cancer
       
    No strong opinion
       
     
    Going beyond cervical cancer: Other cancers and diseases related to HPV
    Recommended HPV vaccination schedules and approved indications
    The role of primary care providers in education and overcoming vaccine hesitancy
    Take CE/CME Test
    Genitourinary Cancer, Gynaecological Cancers, Head and Neck Cancer CE/CME accredited

    touchIN CONVERSATION
    A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation. Close

    Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

    Faculty Podcast Featured
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Evaluate the burden of oncological and non-oncological HPV-related diseases beyond cervical cancer
    • Plan appropriate HPV vaccination schedules for different patient groups
    • Design strategies to improve vaccine uptake in different healthcare settings, from primary to specialized care
    Overview

    In this activity, two experts (a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health) share insights on the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across different healthcare settings. read more

    This activity is jointly provided by USF Health and touchIME.
    touchIME is an EBAC® accredited provider.

    Target Audience

    Paediatricians, family and primary care physicians, internal medicine specialists, obstetricians/gynaecologists, oncologists, dermatologists, urologists, dentists, nurses and nurse practitioners, physician associates and pharmacists involved in HPV vaccination or managing individuals who may have HPV-related diseases.

    USF Accreditation

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Dr Marc Steben discloses: Consultant/advisory fees from GSK and Merck. Speakers’ bureau fees from GSK and Merck. Other fees from Abbott, Attila, GSK, Hologic, Laboratoire Médical Biron, Merck and Roche Molecular Systems. Grant/research fees from Abbott, Attila, GSK, Hologic, Laboratoire Médical Biron, Linepharma, Lupin, Merck, Project PAVE and Project INTEGRATE, and Roche Molecular Systems. Ownership fees from Communications Action-Santé Inc.

    Dr Barbara Moscicki discloses: Advisory board or panel fees from Merck.

    Content Reviewer

    Pharmacist planner and reviewer, Angela Massey Hill, PharmD, CPh, RPh, has no financial interests/relationships or affiliations in relation to this activity.

    Touch Medical Contributors

    Christina Mackins-Crabtree and Gemma Corr have no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu 

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 20 February 2025. Date credits expire: 20 February 2028.

    If you have any questions regarding credit, please contact cpdsupport@usf.edu

    Pharmacists

    USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.75 hours (0.075 CEUs).  Universal program number is as follows: 0230-9999-25-002-H06-P.

    This activity can be viewed on any web browser such as, but not limited to, Google Chrome, Firefox, Safari, Opera, Microsoft Edge and Internet Explorer.

    Date of original release: 20 February 2025. Date credits expire: 20 February 2028.

    If you have any questions regarding credit please contact cpdsupport@usf.edu

    Nurses

    USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    A maximum of 0.75 contact hour(s) may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

    This activity is awarded 0.75 ANCC pharmacotherapeutic contact hour.

    Date of original release: 20 February 2025. Date credits expire: 20 February 2028.

    If you have any questions regarding credit please contact cpdsupport@usf.edu

    EBAC® Accreditation

    touchIME is an EBAC® accredited provider since 2023.

    This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 50 minutes of effective education time.

    The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.

    Faculty Disclosure Statement / Conflict of Interest Policy

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

    Faculty

    Dr Marc Steben discloses: Consultant/advisory fees from GSK and Merck. Speakers’ bureau fees from GSK and Merck. Other fees from Abbott, Attila, GSK, Hologic, Laboratoire Médical Biron, Merck, NCI and Roche Molecular Systems. Grant/research fees from Abbott, Attila, GSK, Hologic, Laboratoire Médical Biron, Linepharma, Lupin, Merck, Project PAVE and Project INTEGRATE, and Roche Molecular Systems. Ownership fees from Communications Action-Santé Inc.

    Dr Barbara Moscicki discloses: Advisory board or panel fees from Merck.

    Requirements for Successful Completion

    Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.

    Date of original release: 20 February 2025. Date credits expire: 20 February 2027.

    Time to Complete: 50 minutes

    If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org 

     

    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    Topics covered in this activity

    Genitourinary Cancer / Gynaecological Cancers / Head and Neck Cancer
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now

    Journal articles and more to your inbox

    Get the latest clinical insights from touchONCOLOGY

    Sign me up!
    This Activity Is Funded By:

    An independent medical education grant from Merck Sharp & Dohme LLC.

    This activity is jointly provided by USF Health and touchIME.
    touchIME is an EBAC® accredited provider.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Date of original release: 20 February 2025. Date credits expire: 20 February 2028.

    EBAC® 

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside the UK.

    Claim Credit
    touchIN CONVERSATION
    Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals
    0.75 CE/CME credit
    Question 1/5
    Which HPV types are most commonly associated with non-cervical cancers, such as anal, penile and oropharyngeal cancers?

    HPV, human papillomavirus.

    There are 12 high-risk HPV types currently recognized to cause cancer in humans (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59).1 High risk varies by type, with HPV16 being the most oncogenic.1 HPV types 16 and 18 are associated with 85% of HPV-related head and neck cancers and 87% of anal cancers.1 Among HPV DNA-positive penile and vulvar cancers, HPV16 is the most common HPV type.2,3

    Abbreviation

    HPV, human papillomavirus.

    References

    1. World Health Organization. Weekly epidemiological record. 2022;97:645–72.
    2. Oelsen TB, et al. Lancet Oncol. 2019;20:145–58.
    3. Smith JS, et al. Obstet Gynecol. 2009;113:917–24.
    Question 2/5
    You are educating a group of HCPs about HPV vaccination. Which of the following best highlights the broader benefit of HPV vaccination beyond cervical cancer prevention?

    HCP, healthcare professional; HPV, human papillomavirus.

    Infection with high-risk HPV is associated with cancers of the oropharynx and anus in both genders, with penile cancer in men, and with vulval and vaginal cancers in women.1 Projections suggest that HPV vaccination will reduce the rate of oropharyngeal cancers in younger adults (age 36–55) in the period 2018–2045.2 In men, HPV vaccination has been shown to reduce oral HPV positivity, suggesting a likely reduction in future oropharyngeal cancer development.3 In young women (age 17–32), HPV vaccination was associated with a 70% reduction in the risk of developing anal high-grade precancerous lesions or worse.4 The quadrivalent vaccine was also shown to reduce anal HPV infection rates and the incidence of grade 1–3 anal intraepithelial neoplasia in men, likely indicating an impact on future anal cancer development.5

    Abbreviation

    HPV, human papillomavirus.

    References

    1. World Health Organization. Weekly epidemiological record. 2022;97:645–72.
    2. Zhang Y, et al. JAMA Oncol. 2021;7:e212907.
    3. Macilwraith P, et al. Infect Agent Cancer. 2023;18:24.
    4. Baandrup L, et al. J Natl Cancer Inst. 2024;116:283–87.
    5. Palefsky JM, et al. N Engl J Med. 2011;365:1576–85.
    Question 3/5
    A 9-year-old child attends your clinic with a parent to discuss their routine vaccinations, including HPV. The child received a kidney transplant at age 7 and is continuing to receive immunosuppressive therapy. Assuming availability of the HPV vaccine in your clinic, what would you do?

    HPV, human papillomavirus.

    The WHO, and the CDC in the USA, recommend immunocompromised people, which includes those who have received a solid organ transplant, should ideally receive three doses of HPV vaccine,1,2 with doses given at 0, 1–2 and 6 months.2 It is optimal to try to vaccinate prior to organ transplant if possible.3

    Abbreviations

    CDC, Centers for Disease Control and Prevention; HPV, human papillomavirus; WHO, World Health Organization.

    References

    1. WHO. Weekly epidemiological record. 2022;97:645–72.
    2. CDC. Administering HPV Vaccine. Available at: www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html (accessed 17 January 2025).
    3. Nailescu C, Shew ML. Front Pediatr. 2022;10:1057454.
    Question 4/5
    When considering how to improve HPV vaccine uptake in children and adolescents, which strategies can be helpful?

    HPV, human papillomavirus.

    The CDC in the USA provides guidance on five steps to boost HPV vaccination rates.1 These include bundling an HPV vaccine recommendation with other routine vaccinations, ensuring a consistent message from all staff, using every opportunity to vaccinate, providing personal examples and effectively answering questions.1 In a survey of parents of adolescents, receiving a high quality recommendation (mentioning that the HPV vaccine was very/extremely important, that it prevented multiple cancers, and/or that it should be given the same day) led to nine-times higher odds of initiating HPV vaccination.2 Evidence suggests that describing the HPV vaccine as preventative against multiple cancers increases vaccine uptake.3

    Abbreviations

    CDC, Centers for Disease Control and Prevention; HPV, human papillomavirus.

    References

    1. CDC. HPV vaccination recommendations. Available at: www.cdc.gov/hpv/hcp/vaccination-considerations/boost-rates.html (accessed 20 January 2025).
    2. Gilkey MB, et al. Vaccine. 2016;34:1187–92.
    3. Brewer NT, et al. Hum Vaccin Immunother. 2023;19:2216117.
    Question 5/5
    You are discussing HPV vaccination with a child and their mother. The mother is reluctant to have the child vaccinated against HPV, as she doesn't understand the purpose of the vaccine, especially as her child is not sexually active. What counsel would you provide to maximize the chance of uptake?

    HPV, human papillomavirus.

    Evidence suggests that describing the HPV vaccine as preventative against multiple cancers increases vaccine uptake.1 Further, recommending that the vaccine is given the same day encourages uptake.1 The WHO recommends HPV vaccination should ideally be given before individuals are sexually active2 and several studies indicate that vaccination at a younger age is associated with a stronger immune response to HPV.3

    Abbreviations

    HPV, human papillomavirus; WHO, World Health Organization.

    References

    1. Brewer NT, et al. Hum Vaccin Immunother. 2023;19:2216117.
    2. WHO. Weekly epidemiological record. 2022;97:645–72.
    3. St Sauver JL, et al. Prev Med. 2016:89:327–33.
    Back to Activity

    You may also be interested in...

    This Activity Is Funded By:

    An independent medical education grant from Merck Sharp & Dohme LLC.

    This activity is jointly provided by USF Health and touchIME.
    touchIME is an EBAC® accredited provider.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Date of original release: 20 February 2025. Date credits expire: 20 February 2028.

    EBAC® 

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals outside the UK.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup